Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00261586
Other study ID # CR002500
Secondary ID
Status Completed
Phase Phase 4
First received December 2, 2005
Last updated June 28, 2011
Est. completion date March 2004

Study information

Verified date June 2011
Source Johnson & Johnson Consumer and Personal Products Worldwide
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare several analgesics given in approved daily doses in combination with a daily cardioprotective dose of aspirin (81 mg), to study their bleeding properties and their effects on the stomach in healthy volunteers.


Description:

The purpose of this randomized, multiple-dose, single-blind, parallel-group study is to examine in healthy volunteers the effects of analgesics given in approved daily doses in addition to daily cardio-protective doses of aspirin (81 mg) on the stomach. All subjects are examined endoscopically before receiving study medication, and at the end of treatment on Day 9. Each subject takes 81 mg of aspirin daily plus one of the following treatments to be taken daily on Days 1 through 8: four doses of acetaminophen 1000 mg, three doses of ibuprofen 400 mg, two doses of naproxen sodium (440 mg in the morning and 220 mg in the evening), four doses of aspirin 650 mg, two doses of celecoxib 200 mg, one dose of rofecoxib 25 mg, or no additional study medication. On Day 9, one dose of aspirin 81 mg and only one dose of the assigned treatment drug are taken prior to having an endoscopy. The primary endpoints of the study are the effects of the analgesics on the inhibition of COX-1 activity by aspirin, and any injury to the stomach mucosa, as determined by direct endoscopic observation. Safety assessments consist of routine monitoring for adverse events, as well as endoscopic examination of gastric mucosa for erosions and ulcerations occurring during the treatment phase. The study hypothesis is that the effects of acetaminophen on the stomach do not differ from the effects of ibuprofen, naproxen, aspirin, celecoxib, or rofecoxib. 81 mg aspirin and 1of 7 treatments for 8 days: acetaminophen 1000mg 4xday, ibuprofen 400mg 3xday, naproxen 440mg morning and 220mg evening, no additional study medication, aspirin 650mg 4xday, celecoxib 200mg 2xday,rofecoxib 25mg 1xday. On Day 9, 1 dose aspirin & 1 dose study drug before endoscopy.


Recruitment information / eligibility

Status Completed
Enrollment 92
Est. completion date March 2004
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- In general good health with normal hemostatic (blood coagulation) parameters

- able to swallow study medication

- non-smoker

- negative for H. pylori infection

- if female, must not be pregnant or breast feeding

Exclusion Criteria:

- Have taken anti-inflammatory drugs within one week of study entry, any analgesic within 24 hours before baseline endoscopy, or systemic steroids within 6 weeks of study entry

- unable to tolerate oral drugs or have had gastrointestinal disease or prior gastrointestinal surgery that could interfere with the study medication

- unable to understand or follow instructions

- have a medical condition or clinically significant abnormal laboratory results that may be relevant to participation in the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Consumer and Personal Products Worldwide

Outcome

Type Measure Description Time frame Safety issue
Primary Percent arachidonic acid-induced platelet aggregation; Lanza Mucosal Injury Score of the stomach
Secondary Serum thromboxane B2; plasma PGE2; shear-induced platlet aggregation; cyclooxygenase activity in stomach mucosal biopsies as assessed by PGE2 content
See also
  Status Clinical Trial Phase
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Recruiting NCT05089526 - Opioid-free Anesthesia in Laparoscopic Cholecystectomies N/A
Terminated NCT04489420 - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM Phase 1
Completed NCT03761433 - Intraoperative Nociception and Postoperative Pain
Recruiting NCT04622904 - Lidocaine and Magnesium and Ketamine in Gynecological Surgery N/A
Recruiting NCT05717361 - Opioid Sparing Anesthesia in Cervical Spine Surgery N/A
Completed NCT04818086 - Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Phase 1/Phase 2
Completed NCT04254081 - Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion Phase 4
Recruiting NCT03655847 - Acceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection Phase 4
Completed NCT02085577 - The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients Phase 4
Completed NCT01387750 - Mentholated Cream Containing Oxygenated Glycerol Triesters on Acute Pain of the Muscles and Joints Phase 1/Phase 2
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Active, not recruiting NCT04309084 - Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Phase 1
Completed NCT04369950 - Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine Phase 4
Recruiting NCT05243940 - Opioid-free Anesthesia in Thyroidectomies N/A
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Enrolling by invitation NCT06402149 - Comparison of 2 Different Methods in Infraclavicular Block
Completed NCT03585088 - The Prediction for Postoperative Pain N/A
Not yet recruiting NCT06462196 - Natural History of Depression, Bipolar Disorder and Suicide Risk
Completed NCT02046681 - Monitoring Side Effects Of Pain Medication Prescribing By Emergency Department In Patients Over 65 N/A